Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
China Advances Drug Regulatory Reform amid Slowing Growth
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on recent pharma market data showing slower growth in 2017 a... (12/29/2017)
   
Made in China: New and Potentially Lifesaving Drugs (1/19/2018)
Update on US Investigation of China's IP Practices (1/19/2018)
Fosun-Backed Shanghai Henlius Biotech Eyes IPOs on Both Mainland and HK Stock Markets (1/19/2018)
Hua Medicine Mulls Hong Kong IPO as Diabetes Drug Enters Crucial Clinical Trial Phase (1/18/2018)
New Opportunities in Emerging Markets (1/18/2018)
China's Medical Representative Registration System: Action Items for Pharmaceutical Companies (1/17/2018)
Action Plan on Protection of IPRs of Foreign-Invested Enterprises (1/16/2018)
China's Recent Development on Granting Biological Sequence Claims (1/11/2018)
CFDA Seeks Comments on the Amendments of Administrative Measures for Drug Registration (1/11/2018)
New Circular Further Enhancing the Development of the MAH Regime (1/9/2018)
Amendments Of Anti-Unfair Competition Law (1/4/2018)
China FDA Solicits Comments on Conditional Approvals for New Drugs and Compassionate Use of Investigational Drugs (1/2/2018)
China Advances Drug Regulatory Reform amid Slowing Growth (12/29/2017)
How to Protect Trade Secrets in China When Employees Leave (12/28/2017)
New Circular Further Enhancing the Development of the Market Authorization Holder Regime (12/28/2017)
USTR's 2017 Report for China's WTO Compl...  (1/22/2018)
CFDA Solicits Comments on Measures for D...  (1/19/2018)
CFDA Issues Guidance Opinions for Furthe...  (1/19/2018)
118 Listed Chinese Pharma Cos Report 201...  (1/19/2018)
Recent Executive Moves  (1/19/2018)
Xiangxue Pharma Ties Up with GE Unit to ...  (1/19/2018)
New Study: 40% of Chinese Adults Suffer ...  (1/19/2018)
Chinese and American Scientists Find New...  (1/19/2018)
Ascletis Seeks Third Round of Funding Th...  (1/19/2018)
Mundipharma to Take Over Marketing of Gr...  (1/19/2018)
CFDA Approves New Indication of Mitsubis...  (1/19/2018)
USDOC Points Out "Shortcomings" in China...  (1/19/2018)
CITIC Capital Becomes Controlling Shareh...  (1/19/2018) (free)
Fear of Substandard Medicines Lead to Ex...  (1/19/2018)
India to Blacklist Eight Chinese Pharma ...  (1/19/2018) (free)
Global Contract Pharmaceutical Manufacturing Market to R...
White House Task Force Echoes Pharma Proposals
Pharma Industry Reputation Rebounds Somewhat in 2016
Fresenius Steps Up Pharma M&A with Akorn, Merck KGaA...
Global Pharmerging Market to Grow at a CAGR of 12.88% in...
Fear of Substandard Medicines Lead to Expanding Opportunities f...
Data Snapshot: Chinese Hospital Consumption of Cholesterol-Redu...
CPIIC: Chinese Urban Hospital Drug Market Expected to be Flat i...
Review of Chinese Pharmaceutical Distribution Sector Performanc...
SMEI: Chinese Hospital Drug Market Growth Continued to Slide in...
118 Listed Chinese Pharma Cos Report 2017 Performance Guidan...
Xiangxue Pharma Ties Up with GE Unit to Produce Cancer Immun...
Ascletis Seeks Third Round of Funding That Could Exceed US$1...
Mundipharma to Take Over Marketing of Grunenthal's Pain-Reli...
CFDA Approves New Indication of Mitsubishi Tanabe's Novastan...
CFDA Solicits Comments on Measures for Drug Evaluation a...
CFDA Issues Guidance Opinions for Further Strengthening ...
CFDA Releases List of Newly Approved Professional Journa...
CDE Publishes Notice for Office Move
CFDA Issues Guide for Development of Supplemental Drug T...
USTR's 2017 Report for China's WTO Compliance Highlight IP I...
USDOC Points Out "Shortcomings" in China's Pharma IP Arena
WIPO: China Leads Innovation by Quantity
Novartis Lost Gleevec Infringement Lawsuit in China against ...
NDRC Corrects Government Monopoly Violatoins in Pharmaceutic...
India to Blacklist Eight Chinese Pharma Companies for Qu...
EMA Bans Amoxicillin API from Changsheng Pharma after Id...
Fast Rising Price of Chinese APIs Puts Pressure on Botto...
China to Restrict Production of API Producers in 28 Citi...
Asymchem Labs Announces 2nd TGA Inspection of Its Jilin ...
Chinese and American Scientists Find New Approach to Dev...
Suven Granted A Patent in China for NCEs Targeting Neuro...
First Chronic HepB Patient Dosed in China in Transgene's...
Clinical Trials Registered on the CDE Platform Rebound t...
Overview of Chinese Drug Approvals in 2017
New Study: 40% of Chinese Adults Suffer from High Blood ...
Type 1 Diabetes on the Rise in China, Most New Cases in ...
Numerous Provinces Expand Disease Group-Based BMI Paymen...
NHFPC Outlines Ten Areas of Reform Action in the New Yea...
More Young People Suffering from Colorectal Cancer in Ch...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
CASS: Chinese Economy May See 25% Drop without Populatio...
Upcoming Event: Alzheimer 2018
Upcoming Event: 2nd World Congress on Radiology &...
Upcoming Event: Nursing 2018
Upcoming Event: Analytical Techniques 2018
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links